Cyclo(RGDyK) Trifluoroacetate
Need Assistance?
  • US & Canada:
    +
  • UK: +

Cyclo(RGDyK) Trifluoroacetate

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with IC50 of 20 nM.

Category
Peptide Inhibitors
Catalog number
BAT-010216
CAS number
250612-42-1
Molecular Formula
C31H43F6N9O12
Molecular Weight
847.71
Cyclo(RGDyK) Trifluoroacetate
Size Price Stock Quantity
100 mg $519 In stock
IUPAC Name
2-[(2S,5R,8S,11S)-8-(4-aminobutyl)-11-[3-(diaminomethylideneamino)propyl]-5-[(4-hydroxyphenyl)methyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid; 2,2,2-trifluoroacetic acid
Synonyms
Cyclo (RGDyK); Cyclo RGDyK; Cyclo(RGDyK) trifluoroacetate
Appearance
Solid Powder
Purity
>98%
Sequence
cyclo[Arg-Gly-Asp-D-Tyr-Lys].2TFA
Storage
Store at -20°C
Solubility
Soluble in DMSO (100mg/mL), Water (100mg/mL), Ethanol (20mg/mL)
InChI
InChI=1S/C27H41N9O8.2C2HF3O2/c28-10-2-1-4-18-24(42)34-17(5-3-11-31-27(29)30)23(41)32-14-21(38)33-20(13-22(39)40)26(44)36-19(25(43)35-18)12-15-6-8-16(37)9-7-15;2*3-2(4,5)1(6)7/h6-9,17-20,37H,1-5,10-14,28H2,(H,32,41)(H,33,38)(H,34,42)(H,35,43)(H,36,44)(H,39,40)(H4,29,30,31);2*(H,6,7)/t17-,18-,19+,20-;;/m0../s1
InChI Key
CDDUWKKOPQABPG-TVSMIREGSA-N
Canonical SMILES
C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCCCN)CC2=CC=C(C=C2)O)CC(=O)O.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O
1.Development of long-circulating zwitterionic cross-linked micelles for active-targeted drug delivery.
Lin W, Ma G, Kampf N, Yuan ZF, Chen S. Biomacromolecules. 2016 Apr 6. [Epub ahead of print]
Blood stability, active targeting and controlled drug release are the most important features to design desirable drug carriers. Here, we demonstrate a zwitterionic biodegradable cross-linked micelle based on a block copolymer, which utilizes poly(carboxybetaine methacrylate) (PCBMA) as hydrophilic segment, poly(ε-caprolactone) (PCL) as biodegradable hydrophobic segment, poly(S-2-hydroxyethyl-O-ethyl dithiocarbonate methacrylate) (PSODMA) block as thiol protecting segment for cross-linking, and cyclic Arg-Gly-Asp-d-Tyr-Lys [c(RGDyK)] as targeting ligand. As a result, this micelle possessed excellent colloidal stability at high dilution and in 50% fetal bovine serum (FBS). In vitro drug release experiment showed no burst release under physiological conditions but accelerated drug release in mimicking tumor tissue environment. In vivo tests showed that the drug-loaded micelles had prolonged half-life in bloodstream, enhanced therapeutic efficiency, reduced cardiac toxicity and bio-toxicity compared with free drug formulation.
Online Inquiry
Verification code
Inquiry Basket